Every meaningful development in the 2026 peptide regulatory story, FDA actions, enforcement, and industry shifts, explained in plain language, with what each means for legitimate access.
On July 23–24, 2026 the FDA's advisory committee recommended 6 of 7 peptides for the 503A compounding list — over the objection of the FDA's own scientists. The vote is non-binding: the agency must still complete formal rulemaking before anything changes, and it has signaled it may not adopt every recommendation. No peptide covered here is FDA-approved today.
One email when the FDA acts on the committee's recommendation, plus plain-language updates as the story develops.